Ultragenyx Pharmaceutical (RARE) Change in Cash (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Change in Cash of -$247.0 million for Q1 2026, down 448.89% year-over-year from $70.8 million in Q1 2025, and down 211.53% on a QoQ basis from $221.5 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Cash data on file, last reported at -$247.0 million in Q1 2026.
- Quarterly Change in Cash fell 448.89% year-over-year to -$247.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.0 million (up 193.62% YoY) and the FY2025 annual result came in at $252.0 million, up 820.0% from the prior year.
- Change in Cash declined to -$247.0 million in Q1 2026 per RARE's latest filing, from $221.5 million in the prior quarter.
- Across five years, Change in Cash topped out at $367.9 million in Q2 2024 and bottomed at -$330.0 million in Q3 2024.
- The 5-year median for Change in Cash is $6.5 million (2022), against an average of -$7.1 million.
- Peak annual rise in Change in Cash reached 2179.24% in 2024, while the deepest fall reached 1035.71% in 2024.
- Tracing RARE's Change in Cash over 5 years: stood at -$258.7 million in 2022, then jumped by 154.11% to $140.0 million in 2023, then plunged by 82.72% to $24.2 million in 2024, then surged by 815.69% to $221.5 million in 2025, then tumbled by 211.53% to -$247.0 million in 2026.
- Per Business Quant, the three latest RARE Change in Cash figures stand at -$247.0 million (Q1 2026), $221.5 million (Q4 2025), and $26.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -247.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -247.00 Mn |
| Dec 31, 2025 | 221.46 Mn |
| Sep 30, 2025 | 26.06 Mn |
| Jun 30, 2025 | 49.49 Mn |
| Mar 31, 2025 | -45.00 Mn |
| Dec 31, 2024 | 24.19 Mn |
| Sep 30, 2024 | -330.05 Mn |
| Jun 30, 2024 | 367.89 Mn |
| Mar 31, 2024 | -97.03 Mn |
| Dec 31, 2023 | 139.99 Mn |
| Sep 30, 2023 | -29.06 Mn |
| Jun 30, 2023 | 16.14 Mn |
| Mar 31, 2023 | -46.07 Mn |
| Dec 31, 2022 | -258.71 Mn |
| Sep 30, 2022 | 233.59 Mn |
| Jun 30, 2022 | 6.51 Mn |
| Mar 31, 2022 | -153.38 Mn |
| Dec 31, 2021 | 100.05 Mn |
| Sep 30, 2021 | -93.34 Mn |
| Jun 30, 2021 | -93.53 Mn |
| Mar 31, 2021 | -329.89 Mn |
| Dec 31, 2020 | 526.04 Mn |
| Sep 30, 2020 | -138.15 Mn |
| Jun 30, 2020 | 37.45 Mn |
| Mar 31, 2020 | -135.29 Mn |
| Dec 31, 2019 | 311.01 Mn |
| Sep 30, 2019 | -8.76 Mn |
| Jun 30, 2019 | -137.98 Mn |
| Mar 31, 2019 | 156.45 Mn |
| Dec 31, 2018 | 30.10 Mn |
| Sep 30, 2018 | -27.90 Mn |
| Jun 30, 2018 | -115.88 Mn |
| Mar 31, 2018 | 126.16 Mn |
| Dec 31, 2017 | 40.37 Mn |
| Sep 30, 2017 | -30.34 Mn |
| Jun 30, 2017 | -68.75 Mn |
| Mar 31, 2017 | -2.84 Mn |
| Dec 31, 2016 | 20.04 Mn |
| Sep 30, 2016 | 87.21 Mn |
| Jun 30, 2016 | -15.69 Mn |
| Mar 31, 2016 | -22.81 Mn |
| Dec 31, 2015 | -73.12 Mn |
| Sep 30, 2015 | 114.34 Mn |
| Jun 30, 2015 | -125.69 Mn |
| Mar 31, 2015 | 153.72 Mn |
| Dec 31, 2014 | -29.06 Mn |
| Sep 30, 2014 | 35.94 Mn |
| Jun 30, 2014 | -38.00 Mn |
| Mar 31, 2014 | 48.02 Mn |
| Dec 31, 2013 | 1.38 Mn |
| Sep 30, 2013 | -7.46 Mn |
| Jun 30, 2013 | -51.29 Mn |
| Mar 31, 2013 | -21.39 Mn |